

# Discovery of Candidate T-Cell Antigens for HSV-1 Vaccines

February 20, 2012

J Graham


Herpes simplex virus type 1 (HSV-1) infects 60% of the US population, causing painful oral-labial infections and in some cases, permanent brain damage and blindness. Currently, all candidate HSV vaccines have failed in clinical trials, as they have been unable to stimulate coordinated CD4+ and CD8+ T-cell responses. Due to the large size of the genome and the low frequency of HSV-1-specific T cells, it has been difficult to select the best T cell antigens to be included in a candidate vaccine. To overcome this problem, lead author Lichen Jing and Vaccine and Infectious Disease Division affiliate investigator David Koelle have developed a novel method to efficiently generate a genome-wide map of responsiveness of HSV-1-specific T cells.

HSV-1-specific CD8+ T cells were detected and enriched using cross-presentation, in which HSV-1 antigen loaded dendritic cells presented the antigen to the T cells. Next, CD4+ T cells were reactivated by exposure to the whole killed HSV-1 antigen. Then, both types of HSV-1-specific T cells were enriched by selecting for CD137, a protein that identifies recently activated CD4+ and CD8+ T-cells. By sorting these specific cells from study participants, the cells could then be expanded for downstream testing to determine which antigens were most reactive. Because each person has a unique set of antigen presentation HLA genes, a personalized set of designer cells was created for the CD8+ T-cell discovery work.

The Koelle Lab found that the proteins for HSV-1 genes UL39 and UL46, previously not known to be CD8+ T-cell antigens, appeared to be the most useful vaccine candidates for coordinating both CD4 and CD8 T-cell responses. The gD antigen, which had previously been unsuccessful in a phase III clinical trial, was identified as a poor CD8+ T-cell antigen using this novel approach. Importantly, these methods were also successful for radically enriching CD8 and CD4 T-cells reactive with vaccinia virus. The methods outlined in this report may help streamline the antigen selection process for other pathogens with large genomes.

[Jing L, Haas J, Chong TM, Bruckner JJ, Dann GC, Lichun D, Marshak JO, McClurkan CL, Yamamoto TN, Bailer SM, Laing KJ, Wald A, Verjans GMGM, Koelle DM](#). 2012. Cross-presentation

and genome-wide screening reveal candidate T cells antigens for a herpes simplex virus type 1 vaccine. *Journal of Clinical Investigation*; 122(2): 654–673



Thanks to Mindy Miner, PhD, for technical art